Barclays repeats its overweight rating on biosolutions company Novonesis with a price target of DKK 500.
The bank expects organic sales growth of 5.9 percent in the third quarter. Food & Beverage is expected to grow 14 percent and offset a 7 percent decline in Human Health. The forecast for full-year 2026 is unchanged at 7.8 percent.
Barclays believes that weakness in Human Health is short-term, while Food & Beverage, Household Care and Bioenergy continue to perform strongly.
